BXM Wealth LLC Sells 25,728 Shares of Abbott Laboratories $ABT

Posted by Stanley Muller on Jun 30th, 2026

BXM Wealth LLC cut its position in Abbott Laboratories (NYSE:ABT – Free Report) by 89.4% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 3,044 shares of the healthcare product maker’s stock after selling 25,728 shares during the quarter. BXM Wealth LLC’s holdings in Abbott Laboratories were worth $313,000 at the end of the most recent reporting period.

Several other large investors also recently added to or reduced their stakes in ABT. MidAtlantic Capital Management Inc. bought a new stake in shares of Abbott Laboratories in the fourth quarter valued at approximately $25,000. Cornerstone Financial Management LLC purchased a new stake in shares of Abbott Laboratories during the fourth quarter worth $25,000. Purpose Unlimited Inc. purchased a new position in shares of Abbott Laboratories in the fourth quarter valued at $25,000. Portfolio Resources Advisor Group Inc. purchased a new stake in Abbott Laboratories during the 4th quarter worth about $26,000. Finally, Abound Financial LLC purchased a new position in Abbott Laboratories during the 4th quarter valued at about $26,000. Hedge funds and other institutional investors own 75.18% of the company’s stock.

Insider Buying and Selling

In other Abbott Laboratories news, CFO Philip P. Boudreau bought 2,200 shares of the firm’s stock in a transaction that occurred on Thursday, April 23rd. The stock was bought at an average price of $91.50 per share, for a total transaction of $201,300.00. Following the completion of the acquisition, the chief financial officer directly owned 2,200 shares in the company, valued at $201,300. The trade was a ∞ increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Daniel J. Starks acquired 10,000 shares of the firm’s stock in a transaction on Monday, April 27th. The stock was bought at an average price of $92.65 per share, with a total value of $926,500.00. Following the completion of the acquisition, the director directly owned 6,751,103 shares in the company, valued at approximately $625,489,692.95. This represents a 0.15% increase in their position. The SEC filing for this purchase provides additional information. Corporate insiders own 0.46% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts have recently commented on ABT shares. Mizuho cut their price objective on shares of Abbott Laboratories from $125.00 to $115.00 and set a “neutral” rating for the company in a research report on Friday, April 17th. Royal Bank Of Canada decreased their price target on shares of Abbott Laboratories from $135.00 to $130.00 and set an “outperform” rating on the stock in a report on Friday, April 17th. Raymond James Financial decreased their target price on Abbott Laboratories from $130.00 to $115.00 and set an “outperform” rating on the stock in a research note on Friday, April 17th. Wells Fargo & Company cut their price objective on Abbott Laboratories from $122.00 to $109.00 and set an “overweight” rating for the company in a report on Friday, April 17th. Finally, Barclays cut their price target on shares of Abbott Laboratories from $144.00 to $143.00 and set an “overweight” rating for the company in a research note on Monday, April 20th. Two research analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, Abbott Laboratories presently has a consensus rating of “Moderate Buy” and a consensus target price of $118.30.

Read Our Latest Stock Report on Abbott Laboratories

Abbott Laboratories Stock Performance

NYSE ABT opened at $92.78 on Tuesday. The firm has a market cap of $161.60 billion, a price-to-earnings ratio of 25.99, a PEG ratio of 1.62 and a beta of 0.63. The company has a 50-day simple moving average of $89.03 and a two-hundred day simple moving average of $105.07. The company has a quick ratio of 1.01, a current ratio of 1.39 and a debt-to-equity ratio of 0.56. Abbott Laboratories has a 12-month low of $81.97 and a 12-month high of $137.49.

Abbott Laboratories (NYSE:ABT – Get Free Report) last issued its earnings results on Thursday, April 16th. The healthcare product maker reported $1.15 earnings per share for the quarter, beating the consensus estimate of $1.14 by $0.01. Abbott Laboratories had a return on equity of 17.62% and a net margin of 13.90%.The company had revenue of $11.16 billion during the quarter, compared to analysts’ expectations of $10.99 billion. During the same period in the prior year, the business posted $1.09 EPS. Abbott Laboratories’s quarterly revenue was up 7.8% compared to the same quarter last year. Abbott Laboratories has set its FY 2026 guidance at 5.380-5.580 EPS and its Q2 2026 guidance at 1.250-1.310 EPS. On average, equities analysts forecast that Abbott Laboratories will post 5.48 EPS for the current year.

Abbott Laboratories Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, August 17th. Stockholders of record on Wednesday, July 15th will be issued a dividend of $0.63 per share. This represents a $2.52 dividend on an annualized basis and a dividend yield of 2.7%. The ex-dividend date is Wednesday, July 15th. Abbott Laboratories’s dividend payout ratio is currently 70.59%.

Key Headlines Impacting Abbott Laboratories

Here are the key news stories impacting Abbott Laboratories this week:

Positive Sentiment: The U.S. Justice Department reportedly closed its criminal probe into Abbott’s baby formula operations and chose not to pursue criminal charges, which removes a major overhang and reduces the risk of a damaging legal outcome. US DOJ closes criminal probe into Abbott over baby formula plant, WSJ reports
Positive Sentiment: Abbott’s Medical Devices business is being positioned for another growth phase, with new diabetes, heart rhythm, and electrophysiology products cited as potential drivers ahead of the company’s next earnings update. How Abbott’s Largest Segment Is Preparing for the Next Growth Phase
Neutral Sentiment: Healthcare stocks were modestly higher late Monday afternoon, but Abbott still lagged peers and underperformed the sector, suggesting the stock’s move was more idiosyncratic than industry-wide. Sector Update: Healthcare Stocks Higher Late Afternoon
Neutral Sentiment: Market commentary also highlighted Abbott’s baby formula probe being dropped by the DOJ, reinforcing the legal relief narrative, though investors may still wait for clarity on any civil penalties or follow-on costs. Update: Market Chatter: Abbott Laboratories Baby Formula Probe Dropped by DOJ After Years-Long Investigation Into Contamination Risks
Negative Sentiment: Despite the DOJ news, Abbott’s shares traded lower and underperformed competitors, indicating that investors may be taking profits or focusing on broader concerns around valuation, growth, or lingering legal uncertainty. Abbott Laboratories stock underperforms Monday when compared to competitors

Abbott Laboratories Company Profile

(Free Report)

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.